Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunotherapy with Anlotinib and Chemotherapy in Post-COVID Gastric Cancer
NCT05800080Phase 2Unknown
- Sponsor
- Xijing Hospital
- Start
- Apr 2023
- Primary completion
- Feb 2024
- Modality
- Immune Checkpoint Inhibitors, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab, penpulimab in gastric cancer (GC), sponsored by Xijing Hospital. Status: unknown.
02
Drugs
cadonilimabpenpulimab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05800080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05800080.